Journal of Gastroenterology

, Volume 43, Issue 5, pp 397–401

Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab

  • Keisuke Ojiro
  • Makoto Naganuma
  • Hirotoshi Ebinuma
  • Hiroyoshi Kunimoto
  • Shinichiro Tada
  • Haruhiko Ogata
  • Yasushi Iwao
  • Hidetsugu Saito
  • Toshifumi Hibi
Case Report

Abstract

We encountered a case of reactivation of hepatitis B virus after administration of infliximab for Crohn’s disease. The use of infliximab was considered because the patient displayed abdominal symptoms and perianal lesions. Transaminases were normal, and hepatitis B virus (HBV) DNA was undetectable before treatment, so no antiviral treatment was used, and infliximab and low-dose 6-mercaptopurine were administered. This treatment was effective, but liver dysfunction and reactivation of HBV were observed after the fourth injection of infliximab. This is the first report of Crohn’s disease for which infliximab use was continued even after reactivation of HBV was observed. However, liver dysfunction was not improved by lamivudine. Antiviral treatment should be considered before administration of infliximab for patients with HBV.

Key words

Crohn’s disease infliximab HBV 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Candy S, Wright JP, Gerber M, Adams G, Gerig M, Goodman R. A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn’s disease. Gut 1995;37:674–678.PubMedCrossRefGoogle Scholar
  2. 2.
    Ewe K, Press A, Singe C, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 1993;105:367–372.PubMedGoogle Scholar
  3. 3.
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaputopurine: a long-term, randomized, double blind study. N Engl J Med 1980;302:981–987.PubMedGoogle Scholar
  4. 4.
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaputopurine with Crohn’s disease. A meta-analysis. Ann Intern Med 1995;122:132–142.Google Scholar
  5. 5.
    Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029–1035.PubMedCrossRefGoogle Scholar
  6. 6.
    Present DH, Rutgeerts P, Targan SR, Hanauer SB, Mayer L, van Deventer SJ, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–1405.PubMedCrossRefGoogle Scholar
  7. 7.
    Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–885.PubMedCrossRefGoogle Scholar
  8. 8.
    Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–2476.PubMedCrossRefGoogle Scholar
  9. 9.
    Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patients with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol 2003;30:1624–1625.PubMedGoogle Scholar
  10. 10.
    Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686–687.PubMedCrossRefGoogle Scholar
  11. 11.
    Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, et al. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci 2005;50:163–166.PubMedCrossRefGoogle Scholar
  12. 12.
    Wendling D, Auge B, Betting D, Lohse A, Huede GL, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005;64:788–789.PubMedCrossRefGoogle Scholar
  13. 13.
    Millonig G, Kern M, Ludwiczec O, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening. World J Gastroenterol 2006;12:974–976.PubMedGoogle Scholar
  14. 14.
    Madonia S, Orlando A, Scimeca D, Olivio M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;4:508–509.CrossRefGoogle Scholar
  15. 15.
    Esteve M, Saro C, Gonzalez-Huix F, Suarex F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease. Gut 2004;53:1363–1365.PubMedCrossRefGoogle Scholar
  16. 16.
    del Valle Garcia-Sanchez M, Iglesias-Flores EM, de Dios-Vega JF, Gomes-Camacho F. Poyato-Ganzalez, Sancho-Zapatero R. Inflamm Bowel Dis 2004;10:701–702.CrossRefGoogle Scholar
  17. 17.
    Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky J, et al. Infliximab therapy for rheumatic disease in patients with chronic hepatitis B or C. J Reumatol 2004;31:107–109.Google Scholar
  18. 18.
    Van Assche GA, Paintaud G, D’Haens G. Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn’s disease but may improve pharmacokinetics. Gastroenterology 2006;130Suppl 2:A923.Google Scholar
  19. 19.
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507–539.PubMedCrossRefGoogle Scholar
  20. 20.
    Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209–220.PubMedCrossRefGoogle Scholar
  21. 21.
    Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-a therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366–1371.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2008

Authors and Affiliations

  • Keisuke Ojiro
    • 1
  • Makoto Naganuma
    • 1
  • Hirotoshi Ebinuma
    • 1
  • Hiroyoshi Kunimoto
    • 1
  • Shinichiro Tada
    • 1
  • Haruhiko Ogata
    • 1
  • Yasushi Iwao
    • 1
  • Hidetsugu Saito
    • 1
  • Toshifumi Hibi
    • 1
  1. 1.Department of Internal Medicine, School of MedicineKeio UniversityTokyoJapan

Personalised recommendations